NASDAQ:ARQLArQule Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ArQule, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.00 0.00 (0.00 %) (As of 01/16/2020) Add Compare Share Today's Range$20.00Now: $20.00▼$20.0050-Day Range$20.00MA: $20.00▼$20.0052-Week Range$3.15Now: $20.00▼$20.45VolumeN/AAverage Volume5.27 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/ABeta2.49 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingArQule has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, ArQule has a potential downside of 12.5% from its current price of $20.00.Amount of Analyst CoverageArQule has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesArQule has received 440 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArQule has received 391 “underperform” votes. (Add your “underperform” vote.)Community SentimentArQule has received 52.95% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote “Outperform” if you believe ARQL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArQule does not currently pay a dividend.Dividend GrowthArQule does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ArQule insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.80% of the stock of ArQule is held by insiders.Percentage Held by Institutions74.63% of the stock of ArQule is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ArQule are expected to decrease in the coming year, from ($0.37) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ArQule is -125.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ArQule is -125.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArQule has a P/B Ratio of 27.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARQL Previous Symbol CUSIP04269E10 CIK1019695 Webwww.arqule.com Phone781-994-0300Debt Debt-to-Equity Ratio0.08 Current Ratio8.27 Quick Ratio8.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.76 million Price / Sales93.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book27.78Profitability EPS (Most Recent Fiscal Year)($0.16) Net Income$-15,480,000.00 Net Margins-805.61% Return on Equity-33.10% Return on Assets-26.87%Miscellaneous Employees36 Outstanding Shares120,873,000Market Cap$2.42 billion Next Earnings DateN/A OptionableOptionable Receive ARQL News and Ratings via Email Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. ArQule (NASDAQ:ARQL) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of ArQule? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ArQule. How were ArQule's earnings last quarter? ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biotechnology company earned $0.21 million during the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative net margin of 805.61% and a negative return on equity of 33.10%. During the same period in the previous year, the business earned ($0.05) earnings per share. View ArQule's earnings history. What price target have analysts set for ARQL? 9 analysts have issued twelve-month price objectives for ArQule's shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate ArQule's share price to reach $17.50 in the next twelve months. This suggests that the stock has a possible downside of 12.5%. View analysts' price targets for ArQule. What are Wall Street analysts saying about ArQule stock? Here are some recent quotes from research analysts about ArQule stock: 1. According to Zacks Investment Research, "ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. " (10/31/2019) 2. HC Wainwright analysts commented, "We are initiating coverage with a Buy rating and $13 price target. ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ 531 for B-cell malignancies and miransertib for rare tissue overgrowth diseases. Registrational trials for these two drugs are expected to begin in 2H19. We believe these trials will drive more interest in ArQule and push the stock higher. For the other two products, ARQ 751 and derazantinib, we consider them free call options. Management projects cash and marketable securities on the balance sheet will total approximately $160M at the end of 2019, which is forecast to fund operating expenses into 2022. Targeting treatment resistance in B-cell malignancies." (9/16/2019) Has ArQule been receiving favorable news coverage? Press coverage about ARQL stock has been trending very negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ArQule earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutArQule. Who are some of ArQule's key competitors? Some companies that are related to ArQule include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of ArQule own? Based on aggregate information from My MarketBeat watchlists, some companies that other ArQule investors own include Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Advanced Micro Devices (AMD), Verastem (VSTM), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Celldex Therapeutics (CLDX). Who are ArQule's key executives? ArQule's management team includes the following people: Mr. Paolo Pucci, CEO & Director (Age 58)Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer What is ArQule's stock symbol? ArQule trades on the NASDAQ under the ticker symbol "ARQL." What is ArQule's stock price today? One share of ARQL stock can currently be purchased for approximately $20.00. How big of a company is ArQule? ArQule has a market capitalization of $2.42 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe. What is ArQule's official website? The official website for ArQule is www.arqule.com. How can I contact ArQule? ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
